Clinical trials: Bladder, Overactive
Urge Urinary Incontinence, Overactive Bladder
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo.
- Trial name
- BRIDGES (NCT00862745)
- Testing
- Fesoterodine
- Where
- 13 sites in United States
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Overactive Bladder
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.
- Trial name
- NCT00561951
- Testing
- fesoterodine fumarate
- Where
- 65 sites in Hong Kong, Japan and 2 more
- Volunteers
- 951 people
- Sponsor
- Pfizer
Overactive Bladder Syndrome
Fesoterodine "add-on" Male Overactive Bladder Study
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
- Trial name
- NCT00546637
- Testing
- Fesoterodine
- Where
- 137 sites in United States, Belgium and 17 more
- Volunteers
- 947 people
- Sponsor
- Pfizer
Overactive Bladder
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
- Trial name
- NCT00611026
- Testing
- Tolterodine ER, Fesoterodine
- Where
- 227 sites in United States, Brazil and 23 more
- Volunteers
- 2,417 people
- Sponsor
- Pfizer
Urinary Bladder, Overactive
UK Study Assessing Flexible Dose Fesoterodine in Adults
To explore the effects of fesoterodine when used in a flexible dose manner
- Trial name
- SAFINA (NCT00806494)
- Testing
- Fesoterodine
- Where
- 39 sites in United Kingdom
- Volunteers
- 331 people
- Sponsor
- Pfizer
Overactive Bladder
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
- Trial name
- NCT00658684
- Testing
- fesoterodine fumarate
- Where
- 12 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Pfizer
Urinary Bladder, Overactive
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
- Trial name
- VIBRANT (NCT00573508)
- Testing
- Solifenacin Succinate
- Where
- 59 sites in United States
- Volunteers
- 768 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder
Fesoterodine Flexible Dose Study
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence…
- Trial name
- NCT00536484
- Testing
- Fesoterodine
- Where
- 95 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer